Navigation Links
Northeastern's Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
Date:9/18/2012

Biologic drugs represent one of the most important and fastest growing areas in healthcare today, and especially as these biopharmaceuticals begin to come off patent and developers prepare for biosimilars to hit the market, there is a growing need for advanced analytics throughout the drug development process.

The Barnett Institute of Chemical and Biological Analysis, a part of Northeastern University's College of Science, has recognized this need, and has partnered in the formation of BioAnalytix, LLCa company specializing in the application of advanced biologic drug characterization methods and technologies to enable better, faster and more effective drug development and commercialization.

With a strong and experienced board from the analytical sciences and pharmaceutical industry, the Barnett Institute wanted to help create a company that could directly serve pharmaceutical partners in key areas of biologic development. "Beyond its well established research position in advanced analytics, the Barnett Institute has for several yearsbeen working with leading pharmaceutical companies to develop and apply analytical methods in their areas of biologic development, and we continued to see the increasing opportunity to meet this need as a commercially orientedbusiness," said Barry Karger, Director of the Barnett Institute, James L. Waters Chair in Analytical Chemistry.

"It is really a terrific opportunity to bring leading research and advanced analytic capabilities into a business that can directly help improve and accelerate drug development processes, and reduce costs in the healthcare space overall," said BioAnalytix CEO, Kirt Poss.

The affiliation between the Barnett Institute and BioAnalytix will also enable a mutually beneficial opportunity in joint participation in leading research and policy areas, as well as increased project work with partners in combined areas of advanced research and commercial application,providing even more unique and applied opportunities for Northeastern students. "The spin-off of BioAnalytix not only leads to socially beneficial commercial development that we are not suited to do inside a university, but also keeps our research in contact with the cutting edge of technology in the biologic sector," said Murray Gibson, Dean of Northeastern's College of Science.


'/>"/>

Contact: Lori Lennon
l.lennon@neu.edu
617-680-5129
Northeastern University College of Science
Source:Eurekalert

Related medicine news :

1. Penn Translational Medicine Institute to hold 7th Annual Symposium
2. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
3. Weizmann Institutes mathematical model may lead to safer chemotherapy
4. Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells
5. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
6. Johns Hopkins Armstrong Institute receives $8.9 million patient safety grant
7. Minneapolis Heart Institute Foundation welcomes Europace publication of Optim lead insulation paper
8. Minneapolis Heart Institute Foundation welcomes Europace publication of Optim™ lead insulation paper
9. Researchers awarded National Cancer Institute grants aimed at answering provocative questions
10. JDRF-Helmsley Charitable Trust to fund islet encapsulation research at Diabetes Research Institute
11. A vaccine for heart disease? La Jolla Institute discovery points up this possibility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: